CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04447027
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:32.487335+00:00
Published At: 2025-06-12T00:00:00+00:00
Record Updated At: 2026-01-30
Results Posted At: 2025-06-12
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Cutaneous T-Cell Lymphoma", "Mature T-cell Malignancies", "Peripheral T-Cell Lymphoma", "Relapsed/ Refractory T-cell Malignancies"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-30"
protocolSection.identificationModule.nctId: "NCT04447027"
protocolSection.identificationModule.officialTitle: "A Phase 1 Study of Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-06-12"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.